Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tirrell Johnson"'
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Immunohistology expression of Trop-2 vs response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c28d7d0d017206cdcb8eeb9b98c5f6
https://doi.org/10.1158/1078-0432.22466114
https://doi.org/10.1158/1078-0432.22466114
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47b04cd98cbbe62d66c192352ea6bce
https://doi.org/10.1158/1078-0432.22466111
https://doi.org/10.1158/1078-0432.22466111
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Case Study 2: Response assessment by CT with Trop-2 expresssion by immunohistology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6d62d52a1e1fdc6fd496fb97b50595e
https://doi.org/10.1158/1078-0432.22466117
https://doi.org/10.1158/1078-0432.22466117
Autor:
Allyson J. Ocean, David M. Goldenberg, Pius Maliakal, Michael J. Guarino, William A. Wegener, Kevin Kalinsky, Alexander Starodub, D. Ross Camidge, Jamal Misleh, Wells A. Messersmith, Boyd Mudenda, Robert M. Sharkey, Jhanelle E. Gray, Ebenezer A. Kio, Leena Gandhi, Tirrell Johnson, Gregory A. Masters, Bryan J. Schneider, Rebecca S. Heist, Charles J. Schneider, Ronald J. Scheff, W. Thomas Purcell, Serengulam V. Govindan
Publikováno v:
Clinical Cancer Research. 23:5711-5719
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e3588f6c198004cae5f52ab2059f6c0
https://doi.org/10.1158/1078-0432.ccr-17-0933
https://doi.org/10.1158/1078-0432.ccr-17-0933
Autor:
Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Bryan J. Schneider, Robert M. Sharkey, Pius Maliakal, William A. Wegener, Michael J. Guarino, Charles J. Schneider, Serengulam V. Govindan, Boyd Mudenda, Leena Gandhi, D. Ross Camidge, Tirrell Johnson, Jamal Misleh, Allyson J. Ocean, Rebecca S. Heist, Kevin Kalinsky, David M. Goldenberg, Jhanelle E. Gray, Alexander Starodub
Publikováno v:
Cancer Research. 77:CT155-CT155
Introduction: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) delivering SN-38, a topoisomerase-1 inhibitor, to mSCLC cells expressing Trop-2. We are studying the safety/tolerability and efficacy of IMMU-132 in patients with rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bf1a5376ac8f14cabf50b3874b8138b
https://doi.org/10.1158/1538-7445.am2017-ct155
https://doi.org/10.1158/1538-7445.am2017-ct155